Aug 03, 2023 / 08:30AM GMT
Unidentified Company Representative -
Welcome everyone to Hikma's interim results Q&A. We have Said Darwazah, our CEO; Khalid Nabilsi, our Chief Financial Officer; and Riad Mishlawi, President of Injectables, and our incoming CEO. So welcome everyone. We hope that you have all had a chance to review the presentation. And we will use this session for Q&A. (Operator Instructions) With that, I will hand to Said.
Said Samih Taleb Darwazah - Hikma Pharmaceuticals PLC - Executive Chairman & CEO
Again, good morning, everybody. And welcome to Hikma's results for the first half. As you can see, we think that every division has performed extremely well.
The Injectables have shown good growth. And I will explain later that there were some extra costs on that division. I will explain in detail what they were. But the growth in sales was good, launch of products was good.
We are able to launch a lot of what we call 505(b)(2) products. And these are products typically that are new to the market. So they are like in between a generic and the branded for
Half Year 2023 Hikma Pharmaceuticals PLC Earnings Call Transcript
Feb 13, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers